文献速递淋巴瘤造血干细胞移植与细胞治疗

以泽布替尼为基础的桥接方案在复发/难治弥漫大B细胞淋巴瘤嵌合抗原受体T细胞治疗中的疗效与安全性分析

[Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

回顾性分析21例高危复发/难治弥漫大B细胞淋巴瘤患者,采用以泽布替尼为基础的联合方案桥接CD19 CAR-T细胞治疗,中位随访24.8个月,客观缓解率81.0%,完全缓解率52.4%,1年无进展生存率52.4%,1年总生存率80.1%,细胞因子释放综合征均为1~2级。

要点

  • 21例高危r/r DLBCL患者接受泽布替尼为基础方案桥接CD19 CAR-T治疗。
  • 客观缓解率81.0%,完全缓解率52.4%,中位无进展生存12.8个月。
  • 细胞因子释放综合征均为1~2级,安全性良好。

核心结论

  • 以泽布替尼为基础的联合治疗作为CAR-T桥接方案治疗r/r DLBCL临床有效性高且安全性良好。

研究设计与样本

  • 回顾性分析同济大学附属同济医院血液科和浙江大学附属第二医院血液科2020年6月至2023年6月收治的21例以泽布替尼为基础的方案桥接CD19 CAR-T细胞治疗的高危r/r DLBCL患者。

主要发现

  • 21例患者中位年龄57岁(范围38~76岁),14例(66.7%)ECOG评分≥2分,18例(85.7%)IPI评分≥3分,3例(14.3%)IPI评分2分且均存在结外受累,14例(66.7%)为双表达DLBCL,7例(33.3%)伴TP53突变。
  • 中位随访24.8个月(95%CI 17.0~31.6),客观缓解率81.0%,11例(52.4%)获完全缓解。
  • 中位无进展生存12.8个月,中位总生存未达到;1年无进展生存率52.4%(95%CI 29.8%~74.3%),1年总生存率80.1%(95%CI 58.1%~94.6%)。
  • 18例(85.7%)发生细胞因子释放综合征,均为1~2级;2例(9.6%)发生1级免疫效应细胞相关中枢神经毒性综合征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To further elucidate the clinical efficacy and safety of a combination regimen based on the BTK inhibitor zebutanil bridging CD19 Chimeric antigen receptor T cells (CAR-T cells) in the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) . Methods: Twenty-one patients with high-risk r/r DLBCL were treated with a zanubrutinib-based regimen bridging CAR-T between June 2020 and June 2023 at the Department of Hematology, Tongji Hospital, Tongji University and the Second Affiliated Hospital of Zhejiang University, and the efficacy and safety were retrospectively analyzed. Results: All 21 patients were enrolled, and the median age was 57 years (range: 38-76). Fourteen patients (66.7%) had an eastern cooperative oncology group performance status score (ECOG score) of ≥2. Eighteen patients (85.7%) had an international prognostic index (IPI) score of ≥3. Three patients (14.3%) had an IPI score of 2 but had extranodal infiltration. Fourteen patients (66.7%) had double-expression of DLBCL and seven (33.3%) had TP53 mutations. With a median follow-up of 24.8 (95% CI 17.0-31.6) months, the objective response rate was 81.0%, and 11 patients (52.4%) achieved complete remission. The median progression-free survival (PFS) was 12.8 months, and the median overall survival (OS) was not reached. The 1-year PFS rate was 52.4% (95% CI 29.8% -74.3%), and the 1-year OS rate was 80.1% (95% CI 58.1% -94.6%). Moreover, 18 patients (85.7%) had grade 1-2 cytokine-release syndrome, and two patients (9.5%) had grade 1 immune effector cell-associated neurotoxicity syndrome. Conclusion: Zanubrutinib-based combination bridging regimen of CAR-T therapy for r/r DLBCL has high efficacy and demonstrated a good safety profile. 目的: 探讨以BTK抑制剂泽布替尼为基础的联合方案桥接CD19嵌合抗原受体T细胞(CAR-T细胞)治疗复发/难治弥漫大B细胞淋巴瘤(r/r DLBCL)的有效性和安全性。 方法: 回顾性分析同济大学附属同济医院血液科和浙江大学附属第二医院血液科在2020年6月至2023年6月期间收治的21例以泽布替尼为基础的方案桥接CD19 CAR-T细胞治疗伴有高危因素的r/r DLBCL患者,观察疗效及安全性。 结果: 研究共纳入21例患者,中位年龄为57(38~76)岁,14例(66.7%)美国东部肿瘤协作组体能状况评分(ECOG评分)≥2分,14例(66.7%)为双表达DLBCL,18例(85.7%)国际预后指数(IPI)评分≥3分,3例(14.3%)IPI评分2分的患者均存在结外受累,7例(33.3%)伴有TP53突变。中位随访24.8(95%CI 17.0~31.6)个月,客观缓解率(ORR)为81.0%,11例(52.4%)患者获完全缓解(CR);中位无进展生存(PFS)时间为12.8个月,中位总生存(OS)时间未达到,1年PFS率为52.4%(95%CI 29.8%~74.3%),1年OS率为80.1%(95%CI 58.1%~94.6%)。18例(85.7%)患者发生了细胞因子释放综合征(CRS),均为1~2级;2例(9.6%)发生1级免疫效应细胞相关中枢神经毒性综合征(ICANS)。 结论: 以泽布替尼为基础的联合治疗作为CAR-T桥接方案治疗r/r DLBCL临床有效性高且安全性良好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Lu Y, Liu H, Ye SG, et al. [Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 38049332. doi:10.3760/cma.j.issn.0253-2727.2023.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。